MYOK News and Press, MyoKardia Inc. From 05/11/20

MyoKardia (NASDAQ: MYOK ) announces positive results from a Phase 3 clinical trial, EXPLORER-HCM , evaluating lead drug mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), an inherited disorder characterized by abnormal thickening of heart muscle leadi...

Highly Statistically Significant Improvements in NYHA Classification, Peak VO 2 , and LVOT Gradient  Observed vs. Placebo Mavacamten Well Tolerated; Safety Results Comparable to Placebo U.S. Regulatory Submission Planned for Early 2021 MyoKardia to Host Conference Call at...

MyoKardia (NASDAQ: MYOK ): Q1 GAAP EPS of -$1.50 misses by $0.11 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BRISBANE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive toward our mission, despite the extraordinary personal and professional disruptions intr...

Hypertrophic cardiomyopathy ("HCM") is a genetic heart disease mostly caused by mutations in one of the many sarcomeric genes. The most prevalent mutations include genes encoding myosin heavy chain (~30% of the HCM patients), myosin-binding protein C (~20% of the HCM patients), and cardiac t...

The stocks of drug developers can rise and fall on the release of clinical trial results, particularly if they are for the company's most advanced drug in development. When the results are positive, the stock will typically shoot up on the optimism, and bad news from the clinic can tank a stock....

MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and Heart Failure with Preserved Ejection Fraction (HFpEF) MyoKardi...

Twist Bioscience (NASDAQ: TWST ) will collaborate with Vanderbilt University Medical Center to supply gene and antibodies for the development of COVID-19 treatments. Also, unit Twist Biopharma will provide custom antibody drug discovery libraries and screen the libraries for potential anti...

Noteworthy events during the week of March 22 - 28 for healthcare investors (some could be canceled/postponed due to COVID-19). More news on: Bristol-Myers Squibb Company, Zogenix, Inc., Heron Therapeutics, Inc., Healthcare stocks news, , Read more ...

BRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a late-breaker session at the upcoming American College of Cardiology’s 69 th Annual Scien...